Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the united states than in Europe

Health Affairs

Volumn 30, Issue 7, 2011, Pages 1375-1381

  Roberts, Samantha A ^a   Allen, Jeff D ^a   Sigal, Ellen V ^a  

^a Friends of Cancer Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; BENDAMUSTINE; BEVACIZUMAB; BORTEZOMIB; CETUXIMAB; CLOFARABINE; DASATINIB; DEGARELIX; ERLOTINIB; EVEROLIMUS; HISTAMINE; IXABEPILONE; LAPATINIB; LENALIDOMIDE; MIFAMURTIDE; NELARABINE; NILOTINIB; PALIFERMIN; PANITUMUMAB; PEMETREXED; PLERIXAFOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TOSITUMOMAB I 131; TRABECTEDIN; UNINDEXED DRUG; VORINOSTAT;

ARTICLE; DRUG APPROVAL; DRUG MARKETING; EUROPE; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE AVAILABILITY; HEALTH CARE ORGANIZATION; UNITED STATES;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CROSS-SECTIONAL STUDIES; DRUG APPROVAL; DRUGS, INVESTIGATIONAL; EUROPE; HUMANS; NEOPLASMS; QUALITY CONTROL; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79960238308     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2011.0231     Document Type: Article

References (33)

1. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 1999;21(2): 309-18.
2. Thambi P, Sausville EA. STI571 (imatinib mesylate): the tale of a targeted therapy. Anticancer Drugs. 2002;13(2):111-4.
3. The FDA and slower cures. Wall Street Journal. 2011 Feb 28.
4. Food and Drug Administration Science Board Subcommittee on Science and Technology. FDA science and mission at risk [Internet]. Silver Spring (MD): FDA; 2007 Nov [cited 2011 May 24]. Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4329b_02_01_FDA%20Report%20on%20Science%20and%20 Technology.pdf
5. Gottlieb S. The FDA is evading the law. Wall Street Journal. 2010 Dec 23.
6. Zakaria F. Finding a strategy for growth. Washington Post. 2011 Jan 4.
7. Miller HI. Risk-averse behavior entrenched at FDA. Genetic Engineering and Biotechnology News [serial on the Internet]. 2007 Oct 1 [cited 2011 May 24]. Available from: http://www.genengnews.com/gen-articles/risk-averse-behaviorentrenched-at-fda/2219/
8. Mundy A. Roche drug faces FDA curb. Wall Street Journal. 2010 Dec 17.
9. Mijuk G. EU backs Avastin for breast cancer. Wall Street Journal. 2011 Mar 2.
10. Food and Drug Administration. General principles: EMEA-FDA parallel scientific advice [Internet]. Silver Spring (MD): FDA; 2009 Jul 22 [cited 2011 May 27]. Available from: http://www.fda.gov/InternationalPrograms/FDABeyondOurBordersForeignOffices/EuropeanUnion/EuropeanUnion/European Commission/ucm114345.htm
11. Makower J, Meer A, Denend L. FDA impact on US medical technology innovation: a survey of over 200 medical technology companies. [place unknown]: Josh Makower; 2010 Nov.
12. Food and Drug Administration, Center for Devices and Radiological Health. CDRH innovation [Internet]. Silver Spring (MD): FDA; 2011 Feb [cited 2011 May 24]. Available from: http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHInnovation/ucm242067.htm
13. Mann BS, Johnson JR, He K, Sridhara R, Abraham S, Booth BP, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res. 2007; 13(8):2318-22.
14. Cobham MV, Donovan D. Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer. Cancer Manag. Res. 2009;1:69-77.
15. Brune M, Castaigne S, Catalano J, Gehlsen K, Ho AD, Hofmann WK, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood. 2006;108(1):88-96.
16. Frampton JE. Mifamurtide: a review of its use in the treatment of osteosarcoma. Paediatr Drugs. 2010; 12(3):141-53.
17. Sessa C, De Braud F, Perotti A, Bauer J, Curigliano G, Noberasco C, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol. 2005;23(9):1867-74.
18. European Medicines Agency. Ceplene: authorisation details [Internet]. London: EMA; 2008 [cited 2011 May 27]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000796/human_med_000691.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124
19. Traynor K. Treanda approved for chronic lymphocytic leukemia. Am J Health Syst Pharm. 2008;65(9):793.
20. Hazarika M, Jiang X, Liu Q, Lee SL, Ramchandani R, Garnett C, et al. Tasigna for chronic and accelerated phase Philadelphia chromosome- positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res. 2008; 14(17):5325-31.
21. Klotz L. Degarelix acetate for the treatment of prostate cancer. Drugs Today (Barc). 2009;45(10):725-30.
22. "Off-label" indications for oncology drug use and drug compendia: history and current status. J Oncol Practice. 2005;1(3):102-5.
23. American Society of Clinical Oncology. Reimbursement for cancer treatment: coverage of off-label drug indications. J Clin Oncol. 2006;24: 3206-8.
24. Carpenter D. Reputation and power: organizational image and pharmaceutical regulation at the FDA. Princeton (NJ): Princeton University Press; 2010.
25. Cohen GI. Clinical research by community oncologists. CA Cancer J Clin. 2003;53(2):73-81.
26. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol. 2007; 25(2):209-16.
27. Kaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clin Pharmacol Ther. 2011;89(2):183-8.
28. Carpenter D, Zucker EJ, Avorn J. Drug-review deadlines and safety problems. N Engl J Med. 2008; 358(13):1354-61.
29. Olson MK. The risk we bear: the effects of review speed and industry user fees on new drug safety. J Health Econ. 2008;27(2):615-42.
30. Grabowski HG, Wang R. Do faster Food and Drug Administration drug reviews adversely affect patient safety? An analysis of the 1992 Prescription Drug User Fee Act. J Law Econ. 2008;51:377-406.
31. Tsimberidou AM, Braiteh F, Stewart DJ, Kuzrock R. Ultimate fate of oncology drugs approved by the US Food and Drug Administration without a randomized trial. J Clin Oncol. 2009;27(36);6243-50.
32. Berndt ER, Gottschalk AHB, Philipson TJ, Strobeck MW. Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates. Nat Rev Drug Discov. 2005; 4:545-54.
33. Hamburg MA. Drug approval isn't a race between the US and the EU. Washington Post. 2011 Feb 4.